Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT10109L for Lateral Canthal Lines
NCT03732833Phase 3Completed
- Sponsor
- Medytox Inc.
- Start
- Nov 2018
- Primary completion
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of nivolumab + botulinumtoxinA in Crow's feet and glabellar lines (3 arms), sponsored by Medytox Inc. Primary endpoint: Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) According to INVESTIGATOR AND PARTICIPANT Assessments of LCL Severity… at Day 30. Started Nov 2018; status: completed.
02
Drugs
nivolumab + botulinumtoxinA
03
Conditions
Crow's feetglabellar lines
Beyond the preview
Go deeper on NCT03732833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03732833.